Dose-finding exploratory study on Azithromycin on senescence in healthy volunteers

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522379-26-00

Acronym

AZISEN

Enrollment

Registered

2025-09-12

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cellular senescence and associated inflammatory status

Brief summary

Primary endpoints of this pilot study will be changes in 1) senescent cell abundance in the blood cells by p16INK4A evaluation; 2) other serum markers of aging/inflammaging

Detailed description

To determine the minimum effective dose, To examine the safety

Interventions

DRUGAzitromicina Teva Italia 200 mg/5 ml polvere per sospensione orale

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Primary endpoints of this pilot study will be changes in 1) senescent cell abundance in the blood cells by p16INK4A evaluation; 2) other serum markers of aging/inflammaging	—

Secondary

Measure	Time frame
To determine the minimum effective dose, To examine the safety	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026